Replies to post #156709 on Biotech Values

[oc631]

Have you completely discounted the possibility that extending treatment from 12w to 16w will make a material difference in the FUSION study?

My opinion is durations beyond 12-weeks could just as likely show lower SVR rates than higher. This is partially based on my on own views that the window of activity in oral therapy is much shorter than with interferon-based. Longer durations didn't boost SVR rates when the Sofo/Riba combo was tested in GT1. This study may have been in nulls so perhaps not a fair comparison.



Do you recall GILD releasing SVR4 rates for either the POSITRON or FISSION studies? Do you recall seeing this data released at a conference poster presentation?